VisionHealth, a digital therapeutics (DTx) company based in Munich, Germany, has raised $3,195,000 in pre-Series A funding. DB Speciality Invest led the financing round.

VisionHealth, founded in 2017 and led by Dr. Sabine Haeussermann, CEO, focuses on digital therapy support for respiratory diseases. The company develops digital health solutions in collaboration with research institutions and selected industry partners, medical experts, and IT experts, enabling sustainable improvements to existing standard therapies for patients with chronic lung diseases such as asthma and COPD.

Using cutting-edge digital healthcare solutions, VisionHealth is enabling real progress and improving therapy standards for patients. With their expertise in respiratory therapy, digitalization, regulations, and marketing, pioneers in digital respiratory treatments have created a unique interdisciplinary, international expertise.

VisionHealth plans to use the fund to finance an extended COPD and asthma study in preparation for the market launch of Kata, an innovative digital therapeutic for improved inhalation. The funds will also be used for regulatory approval in the EU and the United States, as well as the commercial launch of the Kata app in Germany and select European markets.